Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07144280 | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | PHASE3 | RECRUITING | 680 | — | — | Sep 29, 2025 | Mar 10, 2032 | Apr 21, 2026 | 305 | United States, Argentina +26 |
Overall survival defined as the time from the date of randomization to the date of death due to any cause.
| Arm | Type | Description |
|---|---|---|
| PF-08046054 monotherapy | EXPERIMENTAL | PF-08046054 monotherapy |
| Docetaxel monotherapy | ACTIVE_COMPARATOR | Docetaxel monotherapy |
| Name | Type | Description |
|---|---|---|
| PF-08046054 | DRUG | Antibody Drug Conjugate Participants will receive PF-08046054, administered as an IV infusion. |
| Docetaxel monotherapy | DRUG | Participants will receive Docetaxel, administered as an IV infusion. |
Inclusion Criteria * Histologically or cytologically confirmed diagnosis of NSCLC with locally advanced, unresectable Stage IIIB or IIIC not eligible for definitive chemoradiotherapy or metastatic (Stage IV: M1a, M1b, or M1c) disease per the American Joint Committee on Cancer (AJCC) Staging Manual,...